Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT02186847
Active Not Recruiting
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. M... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Lewis and Faye Manderson Cancer Center, Tuscaloosa, Alabama +223 locations
Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Register for Updates
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
NCT01187199
Active Not Recruiting
The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT04390763
Terminated
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated mPDAC.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2025
Locations: Winship Cancer Institute, Atlanta, Georgia +30 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
NCT02047500
Terminated
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Mayo Clinic, Scottsdale, Arizona +4 locations
Conditions: Pancreatic Cancer
Register for Updates
Trial of NanoPac Intratumoral Injection in Lung Cancer
NCT04314895
Completed
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Florida Health, Gainesville, Florida +3 locations
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Register for Updates
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
NCT04585490
Recruiting
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Stanford University, Stanford, California
Conditions: Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Register for Updates
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
NCT06745882
Recruiting
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
NCT05075993
Active Not Recruiting
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND). Lvygen Biopharma will provide as investigational supply LVGN3616, LVGN6051 and LVGN7409 at no cost to the patients on this study. This study will explore antitumor activity of four LVGN3616 and LVGN6051 based regimens in seven selected tumor types:
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
Register for Updates
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
NCT03635567
Completed
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin with or without bevacizumab and paclitaxel plus carboplatin with or without bevacizumab. The prim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Alaska Women's Cancer Care ( Site 1770), Anchorage, Alaska +148 locations
Conditions: Cervical Cancer
Register for Updates
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812
Completed
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Site Reference ID/Investigator #004, Birmingham, Alabama +23 locations
Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
NCT01818063
Completed
This randomized phase II trial studies how well carboplatin and combination chemotherapy with or without veliparib works in treating patients with stage IIB-IIIC breast cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland +2 locations
Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Register for Updates
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05053750
Active Not Recruiting
This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer
Register for Updates